Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cancer-Testis Antigen (NY-ESO-1, MAGE-A1, MAGE-A3) (CTA)
- Target
- CTA
- Molecular classification
- Cancer-testis antigens, Protein
01
Overview
Cancer-testis antigens (CTAs) are a family of proteins with highly restricted expression in normal adult tissues—primarily the testis—and aberrant re-expression in various cancers. NY-ESO-1, MAGE-A1, and MAGE-A3 are prominent members. NY-ESO-1 is one of the most studied and immunogenic CTAs, eliciting strong humoral and cellular immune responses, making it an attractive target for cancer immunotherapy through vaccine development and adoptive cell therapy. However, the heterogeneity of antigen expression within tumors can affect therapeutic efficacy.
- Other names
- NY-ESO-1CTAG1BLAGE2LAGE2BMAGE-A1MAGE-A3
02
Mechanism of action
Vaccine development; Adoptive cell therapy; Checkpoint inhibition combination
03
Biological functions
Unknown physiological function (NY-ESO-1)Immune response elicitation
04
Disease associations
Cancer
05
Safety considerations
Heterogeneity of antigen expression within tumorsPotential for off-target effects in immunotherapy
06
Biomarkers
NY-ESO-1 expression in tumor tissueAntibody levels against NY-ESO-1
Beyond the preview
Go deeper on Cancer-Testis Antigen (NY-ESO-1, MAGE-A1, MAGE-A3) (CTA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cancer-Testis Antigen (NY-ESO-1, MAGE-A1, MAGE-A3) (CTA).